Document:

Amendment to Executive Letter of Reappointment

 

This Amendment to the Executive Letter of Reappointment by and
between Lightlake Therapeutics Inc. (the “Company”) and Roger Crystal (“Crystal”) (collectively, the “Parties”)
dated November 26, 2012 (the “Letter”), is entered into by and between the Company and Crystal on December 31st,
2012 (the “Amendment”).

 

WHEREAS the Letter reengaged Crystal as Chief Executive Officer
(“CEO”) of the Company;

 

WHEREAS the Company has requested that Crystal provide services
beneficial to the Company that are beyond the scope of the Letter (the “Services”);

 

WHEREAS Crystal has not been receiving meaningful cash compensation
to date and has received an amount of options deemed by the Company to be inadequate to retain Crystal as CEO;

 

WHEREAS the Company seeks to retain Crystal as CEO; and

 

WHEREAS the Company seeks to provide Crystal with additional
incentive to remain CEO and perform the Services;

 

NOW THEREFORE, in consideration of the mutual covenants herein
contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties
hereby mutually agree to amend the Letter as follows:

 

		1)	Crystal shall provide the Services until one (1) year from the date hereof.

 

		2)	Any compensation granted herein shall be in addition to any other option compensation previously granted by the Company to
Crystal and in addition to any accrued cash compensation owed by the Company to Crystal.

 

		3)	Effective January 1, 2013, Crystal shall receive annual cash pay of US$300,000.00 unless otherwise agreed in writing by the
Parties. Such pay shall be paid to Crystal in US$75,000.00 quarterly cash installments on the first day of each calendar quarter
of service: January 1, April 1, July 1, and October 1 of each year. Notwithstanding the foregoing, such annual cash pay shall be
deferred until the earlier of the date on which the Company is acquired or the date on which the Company is sufficiently funded
or partially funded, as determined by a majority of the Board of Directors of the Company, at which point all (or a portion of,
if partially funded) unpaid installments to such date on which the Company shall be funded shall be paid to Crystal within a reasonable
amount of time and shall not be unreasonably withheld. Once the Company is appropriately funded, as determined by a majority of
the Board of Directors of the Company, the Company shall pay Crystal competitive and reasonable cash compensation on a quarterly
basis, the amount of which shall be determined in good faith by Crystal and the Company at the time that such funding is received
by the Company.

 

    	 

    	 

    

 

		4)	Crystal shall accrue paid time off (“PTO”) at the rate of 25 days for each calendar year, prorated as applicable
for any particular calendar year and subject to the terms of the Company’s vacation policy. PTO is meant to include all vacation,
personal, and sick days. Crystal shall be compensated at the usual rate of cash compensation for any PTO. Crystal shall also be
entitled to paid Company Holidays as generally given by the Company, which are currently defined to include New Year’s Day,
Memorial Day, Independence Day, Labor Day, the day before Thanksgiving Day, Thanksgiving Day, and Christmas Day.

 

		5)	Crystal shall be eligible to participate in the benefit plans established for Company senior management and officers, including
group life, health, and dental coverage; in each case to the same extent and in the same manner as other similarly situated executives.
Nothing herein shall be constructed to limit, condition or otherwise encumber the Company’s right to amend, discontinue,
substitute or maintain any employee benefits plan, program or perquisite.

 

		6)	Crystal shall be granted the following options, all of which shall vest on the date hereof: (a) stock options for two million
five hundred thousand (2,500,000) shares of stock of the Company, exercisable at US$0.12 with the life of such option being ten
(10) years; and (b) stock options for eight million five hundred thousand (8,500,000) shares of stock of the Company, exercisable
at US$0.15 with the life of such options being five (5) years (collectively, the “Options”). Such Options shall be
exercisable in the form of Notice of Stock Option Grant attached as Exhibit A hereto, which Options may be exercised, where applicable,
pursuant to the form of Notice of Exercise of Stock Option (the “Exercise Notice”) attached as Exhibit B hereto. Notwithstanding
any provisions of the Options to the contrary, if the fair market value of one share of Common Stock (as defined in the Stock Option
Plan of the Company effective December 15, 2010 (the “Stock Option Plan”)) is greater than the relevant exercise price
(“Exercise Price”) (at the date of calculation as set forth below), in lieu of exercising the Options for cash, the
Holder (as defined in the Stock Option Plan) may elect to receive shares equal to the value (as determined below) of the Options
(or the portion thereof being exercised) by surrender of the Options at the principal office of the Company together with the properly
signed Exercise Notice in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the
following formula:

 

	 	X=	Y(A-B)
	 		    A

 

    	 

    	 

    

 

	 	Where X =	the number of shares of Common Stock to be issued to the Holder
	 	 	 
	 	Y =	the number of shares of Common Stock purchasable under the Options or, if only a portion of the Options are being exercised, the portion of the Options being exercised (at the date of such calculation)
	 	 	 
	 	A =	the fair market value of one share of the Company’s Common Stock (at the date of such calculation)
	 	 	 
	 	B =	the Exercise Price per share (as adjusted to the date of such calculation)

 

Notwithstanding the foregoing, such Options referenced
in (b) above may only be exercised between the following dates: (i) the earliest date on which the price per share of the Company’s
Common Stock has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and
(ii) their expiration date. Proportionate adjustments shall automatically be made to both the Exercise Prices and number of all
such Options referenced herein, and the price per share restriction set forth in this paragraph, if applicable, in the event of
a stock split, stock dividend, reclassification, recapitalization, or any other increase or decrease in the number of issued shares
of Company’s Common Stock effected without receipt of consideration by the Company, or upon any other event reasonably determined
by a majority of the Board of Directors of the Company to justify such adjustments.

 

Within one (1) month following the date hereof, the
Company shall deliver to Crystal all Options granted herein. All such Options delivered to Crystal as per this Amendment may be
delivered to Crystal electronically with a scanned signature, in which case they shall have the same effect and force as if they
had been delivered in original signed form. For all Options granted to Crystal electronic delivery of a signed Exercise Notice
along with electronic delivery of such Options shall have the same exercise effect as surrendering such Options at the principal
office of the Company together with the properly signed Exercise Notice.

 

All shares of the Company’s Common Stock underlying
the Options set forth above shall be delivered in registered and freely transferrable form. Within one (1) year from the date hereof,
the Company shall register all such stock under the Securities Act of 1933, as amended, to ensure that registered and freely transferrable
Common Stock shall be delivered to Crystal upon the exercise of the Options. Within one (1) year from the date hereof the Company
shall adopt a stock incentive plan that is tax-efficient for Crystal.

 

    	 

    	 

    

 

		7)	Crystal shall be granted warrants for four million (4,000,000) shares of stock of the Company, exercisable at US$0.15 with
the life of such warrants being five (5) years from the date hereof (the “Warrants”). Such Warrants shall be exercisable
in the form of Notice of Warrant Grant attached as Exhibit C hereto, which Warrants may be exercised, where applicable, pursuant
to the form of Notice of Exercise of Warrant (the “Warrant Exercise Notice”) attached as Exhibit D hereto. The Warrants
shall be exercisable in whole or in part, are only exercisable for cash, and are freely transferable to other parties except as
prohibited by applicable laws and regulations. Subject to the restrictions and requirements of applicable law, the Warrants are
exchangeable at any time for an equal aggregate number of warrants of different denominations, as reasonably requested by the holder
of the Warrants surrendering the same, or in such denominations as may be requested by the holder of the Warrants (but not exceeding
the number of Warrants granted).

 

Notwithstanding the foregoing, such Warrants may only
be exercised between the following dates: (i) the earliest date on which the price per share of the Company’s Common Stock
has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) their
expiration date. Proportionate adjustments shall automatically be made to both the Exercise Price and number of such Warrants,
and the price per share restriction set forth in this paragraph, in the event of a stock split, stock dividend, reclassification,
recapitalization, or any other increase or decrease in the number of issued shares of the Company’s Common Stock effected
without receipt of consideration by the Company, or upon any other event reasonably determined by a majority of the Board of Directors
of the Company to justify such adjustments.

 

Within one (1) month following the date hereof, the
Company shall deliver to Crystal such Warrants in original signed form. For all Warrants granted to Crystal electronic delivery
of a signed Warrant Exercise Notice along with electronic delivery of such Warrants shall have the same exercise effect as surrendering
such Warrants at the principal office of the Company together with the properly signed Warrant Exercise Notice.

 

All shares of the Company’s Common Stock underlying
the Warrants set forth above shall be delivered in registered and freely transferrable form. Within one (1) year from the date
hereof, the Company shall register all such stock under the Securities Act of 1933, as amended, to ensure that registered and freely
transferrable Common Stock shall be delivered to Crystal upon the exercise of the Warrants.

 

    	 

    	 

    

 

		8)	In the event of termination pursuant to Section 6 of the Letter, the Company shall not be obligated to provide any further
compensation to Crystal except such options that have vested, such warrants that have been granted, and any other cash or non-cash
compensation, including deferred cash compensation, to which Crystal is entitled through the date of such termination. Unless severance
is provided for in another agreement between Crystal and the Company, upon any termination of Crystal by the Company that is not
for a reason set forth in Section 6 of the Letter, upon the death of Crystal, or upon a Constructive Termination, the Company shall
pay Crystal the higher of his then current annual cash pay or the annual cash pay set forth herein, in quarterly cash installments
for four quarters from such date of termination, Constructive Termination, or death. Constructive Termination means: (i) a reduction
in annual cash pay or a material adverse change to the incentive plan that affects Crystal differentially and adversely from other
employees, management, and/or officers with comparable levels of responsibility; (ii) upon the Company’s or its successor’s
reasonable request, Crystal refuses to relocate to a facility or location more than fifty (50) miles from Crystal’s current
location; (iii) if Crystal is subjected to discrimination, harassment or abuse as a result of his race, color, religion, creed,
sex, age, national origin, sexual orientation, or disability; (iv) a failure of a successor of the Company to assume the obligations
of this Amendment; or (v) a material breach by the Company of this Amendment.

 

		9)	This Amendment shall be governed by and construed in accordance with the laws of the United States, and specifically the laws
of the state of Nevada. Should a dispute arise, both parties shall subject themselves to exclusive jurisdiction of the courts of
the state of Nevada.

 

		10)	This Amendment and the Letter constitute the entire understanding between the Parties relating to its subject matter, superseding
all negotiations, prior discussions, preliminary agreements and agreements relating to the subject matter hereof made prior to
the date hereof. No waiver by a Party of any breach by another Party of any term, provision or condition of this Amendment, to
be performed by such other Party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same time or
at any prior or subsequent time. This Amendment may not be modified or amended except in writing signed by the Parties. Each of
the Parties hereto agrees that this Amendment has been jointly prepared, and that no claim may be asserted by any Party that any
ambiguity in this Amendment may be construed against any one Party. Except as expressly herein amended, all of the terms and conditions
of the Letter shall continue in full force and effect, and the same are hereby ratified and confirmed. In the event of an inconsistency
or conflict between any terms or conditions in the Letter and in this Amendment, the terms in this Amendment shall govern.

 

    	 

    	 

    

 

		11)	This Amendment may be executed in counterparts, each of which shall constitute an original but together shall constitute one
and the same Amendment. The Parties further agree that such counterparts may be provided via scan, email, and/or facsimile to one
another, each of which shall be binding upon the signatory who sends the scan, email and/or facsimile that was signed by such sending
signatory. The Parties further agree to exchange the original signature pages hereof as soon as practicable after sending such
scan, email and/or facsimile, but in any dispute or controversy, the Parties hereto agree that it shall not be necessary for any
such Party to provide the original signature pages of the other as a condition of enforcing this Amendment, it being understood
that such scan, email and/or facsimile signature pages shall be sufficient to establish the consent of the Party who sent the scan,
email and/or facsimile that was signed by such sending signatory to be bound by the terms of this Amendment.

 

IN WITNESS WHEREOF the parties have executed
this Amendment this 31st day of December 2012.

 

	LIGHTLAKE THERAPEUTICS INC.	 
	 	 	 
	By:	/s/ Roger Crystal	 
	Name:	Roger Crystal	 
	Title:	CEO	 

 

	By:	/s/ Michael Sinclair	 
	Name:	Michael Sinclair	 
	Title:	Chairman	 

 

EXHIBIT A

 

FORM OF NOTICE OF STOCK OPTION GRANT

 

Dear Dr. ________________ (“Optionee”),

 

Reference is hereby made to (i) the Stock Option Plan of Lightlake
Therapeutics Inc. (the “Company”) effective December 15, 2010 (the “Stock Option Plan”),
and (ii) the Executive Letter of Reappointment dated November 26, 2012, between the Company and Roger Crystal and the Amendment
to the Executive Letter of Reappointment dated _______________ __, ____, between the Company and Roger Crystal (as amended, restated,
or otherwise modified from time to time, the “Letter”). Capitalized terms utilized herein shall have the meanings
ascribed to them in the Stock Option Plan unless otherwise defined herein.

 

    	 

    	 

    

 

You have been granted
options to purchase Common Stock of the Company (with each share of Common Stock of the Company, a “Share”)
as follows:

 

	Board Approval Date:	 
	 	 
	Date of Grant:	 
	 	 
	Exercise Price per Share:	[US$0.12 or US$0.15, as appropriate]
	 	 
	Total Number of Shares Granted:	 
	 	 
	Total Exercise Price:	Cashless exercise as per the Letter
	 	 
	Type of Options:	Non-Qualified Stock Options
	 	 
	Expiration Date:	[The date that is ten (10) years or five (5) years from the Date of Grant, as appropriate]
	 	 
	Termination Period:	These Options may be exercised for a period of ten (10) years or five (5) years from the Date of Grant, as appropriate.  Optionee is responsible for keeping track of these exercise periods following termination for any reason of his service relationship with the Company, it being understood that Optionee is entitled to all rights, including compensation and vesting rights, with respect to these Options, as set forth in the Letter.  The Company will not provide further notice of such periods.
	 	 
	Transferability:	These Options may not be transferred, except as permitted by applicable laws and regulations.
	 	 
	Restrictions on Exercise:	[With respect to the Options with the US$0.15 Exercise Price and five (5) year life: These Options may only be exercised between the following dates: (i) the earliest date on which the price per Share has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) the Expiration Date.]  Notwithstanding anything to the contrary contained in any agreement with the Company, it is an absolute condition of the Optionee’s right to exercise any Option that the Optionee be in full compliance with any other agreements between the Optionee and the Company, including without limitation any confidentiality agreements.

 

    	 

    	 

    

 

	Vesting:	100% on [the date of the initial Amendment to the Executive Letter of Reappointment referenced herein]

 

Following receipt by
the Company of evidence and/or an indemnity from the Optionee to the Company in a form reasonably satisfactory to the Company of
the loss, theft, destruction or mutilation of these Options or any certificates for representing the Shares underlying these Options
and, in the event of mutilation, following the surrender and cancellation of such Options or stock certificate, the Company will
make and deliver replacement Options or stock certificate of like tenor and dated as of such cancellation, in lieu of these Options
or stock certificates, without any charge therefor, it being understood that the making and/or delivery of such replacement Options
or stock certificates by the Company will not be unreasonably withheld.  Any such replacement Options or stock certificates
shall be subject to the same terms, conditions, and restrictions as these Options and any Shares underlying these Options. Subject
to the restrictions and requirements of applicable law, these Options are exchangeable at any time for an equal aggregate number
of options of different denominations, as reasonably requested by the Optionee surrendering the same, or in such denominations
as may be requested by the Optionee (but not exceeding the number of Shares underlying the Options in these Options in the aggregate). 
No service charge will be made for such registration or transfer, exchange or reissuance. Proportionate adjustments shall automatically
be made to both the Exercise Price and number of these Options, and the Restrictions on Exercise [if applicable], in the event
of a stock split, stock dividend, reclassification, recapitalization, or any other increase or decrease in the number of issued
Shares of the Company effected without receipt of consideration by the Company, or upon any other event reasonably determined by
a majority of the Board of Directors of the Company to justify such adjustments.

 

Shares issued to you
upon exercise of these Options shall be registered under the Securities Act of 1933, as amended, and shall be freely transferrable.
To the extent that the terms of the Stock Option Plan differ from the terms of this Notice of Stock Option Grant (the “Notice”),
the terms of this Notice supersede the terms of the Stock Option Plan.

 

By your signature and
the signature of the Company’s representative below, you and the Company agree to the terms of these Options.

 

	 	 	LIGHTLAKE THERAPEUTICS INC.
	 	 	 
	 	 	 
	Optionee	 	Dr. Michael Sinclair, Chairman

 

    	 

    	 

    

EXHIBIT B

 

Form of Notice of Exercise of Stock
Option

 

Ladies and Gentlemen:

 

This letter constitutes an unconditional
and irrevocable notice that I hereby exercise the stock option(s) granted to me by Lightlake Therapeutics Inc., a Nevada corporation
(the “Company”) on _______________ at a fair market value of US$ ______ per share. Pursuant to the terms of
such option(s), I wish to purchase _______________ shares of the common stock covered by such option(s) at the exercise price(s)
of US$ ______ per share via cashless exercise. These shares should be registered under the Securities Act of 1933, as amended,
and delivered as follows:

 

	Name:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number:	 	 

 

I represent that I will not dispose of such
shares in any manner that would involve a violation of applicable securities laws.

 

	Dated:  	 	 	By:       	 
	 	 	 	 	 
	 	 	 	Name:  	 

 

    	 

    	 

    

 

EXHIBIT C

 

FORM OF NOTICE OF WARRANT GRANT

 

Dear Dr. ________________ (“Warrant Holder”),

 

As per the Amendment
to the Executive Letter of Reappointment dated _______________ __, ____, between Lightlake Therapeutics Inc. (the “Company”)
and Roger Crystal, the Warrant Holder has been granted warrants (“Warrants”) to purchase Common Stock of the Company
(with each share of Common Stock of the Company, a “Share”) as follows:

 

	Board Approval Date:	 
	 	 
	Date of Grant:	 
	 	 
	Exercise Price per Share:	US$0.15
	 	 
	Total Number of Warrants Granted:	 
	 	 
	Total Exercise Price:	US$0.15 per Warrant
	 	 
	Expiration Date:	[The date that is five (5) years from the Date of Grant]
	 	 
	Termination Period:	These Warrants may be exercised for a period of five (5) years from the Date of Grant.
	 	 
	Transferability:	These Warrants may be transferred, except as prohibited by applicable laws and regulations.
	 	 
	Vesting:	100% on [the date of the initial Amendment to the Executive Letter of Reappointment referenced herein.]
	 	 
	Restriction on Exercise:	These Warrants may only be exercised between the following dates: (i) the earliest date on which the price per Share has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) the Expiration Date.

 

    	 

    	 

    

 

Following receipt by
the Company of evidence and/or an indemnity from the Warrant Holder to the Company in a form reasonably satisfactory to the Company
of the loss, theft, destruction or mutilation of these Warrants or any certificates for representing the Shares underlying these
Warrants and, in the event of mutilation, following the surrender and cancellation of such Warrants or stock certificate, the Company
will make and deliver replacement Warrants or stock certificate of like tenor and dated as of such cancellation, in lieu of these
Warrants or stock certificates, without any charge therefor, it being understood that the making and/or delivery of such replacement
Warrants or stock certificates by the Company will not be unreasonably withheld.  Any such replacement Warrants or stock certificates
shall be subject to the same terms, conditions, and restrictions as these Warrants and any Shares underlying these Warrants. Subject
to the restrictions and requirements of applicable law, these Warrants are exchangeable at any time for an equal aggregate number
of warrants of different denominations, as reasonably requested by the Warrant Holder surrendering the same, or in such denominations
as may be requested by the Warrant Holder (but not exceeding the number of Shares underlying the Warrants in these Warrants in
the aggregate).  No service charge will be made for such registration or transfer, exchange or reissuance. Proportionate adjustments
shall automatically be made to both the Exercise Price and number of these Warrants, and the Restriction on Exercise, in the event
of a stock split, stock dividend, reclassification, recapitalization, or any other increase or decrease in the number of issued
Shares of the Company effected without receipt of consideration by the Company, or upon any other event reasonably determined by
a majority of the Board of Directors of the Company to justify such adjustments.

 

Shares issued to the
Warrant Holder upon exercise of these Warrants shall be registered under the Securities Act of 1933, as amended, and shall be freely
transferrable.

 

By signature of the Warrant
Holder and the signature of the Company’s representative below, the Warrant Holder and the Company agree to the terms of
these Warrants.

 

	 	 	LIGHTLAKE THERAPEUTICS INC.
	 	 	 
	 	 	 
	Warrant Holder	 	Michael Sinclair, Chairman

 

    	 

    	 

    

  

EXHIBIT D

 

Form of Notice of Exercise of Warrant

 

Ladies and Gentlemen:

 

This letter constitutes an unconditional
and irrevocable notice that I hereby exercise the warrant(s) granted to me by Lightlake Therapeutics Inc., a Nevada corporation
(the “Company”) on _______________ at a fair market value of US$ ______ per share. Pursuant to the terms of
such warrant(s), I wish to purchase _______________ shares of the common stock covered by such warrant(s) at the exercise price(s)
of US$ ______ per share via cash exercise, for a total aggregate purchase price of US$_______________, which I agree to promptly
provide to the Company.

 

Electronic delivery of this signed notice along with electronic
delivery of such warrant(s) shall have the same exercise effect as surrendering such warrant(s) at the principal office of the
Company together with the properly signed Notice of Exercise of Warrant.

 

These shares should be registered under the Securities Act of
1933, as amended, and delivered as follows:

 

	Name:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number:	 	 

 

I represent that I will not dispose of such
shares in any manner that would involve a violation of applicable securities laws.

 

	Dated:  	 	 	By:       	 
	 	 	 	 	 
	 	 	 	Name:Amendment to Executive Letter of Appointment

 

This Amendment to the Executive Letter of Appointment by and
between Lightlake Therapeutics Inc. (the “Company”) and Kevin Pollack, Esq. (“Pollack”) (collectively,
the “Parties”) dated November 26, 2012 (the “Letter”), is entered into by and between the Company and Pollack
on December 31st, 2012 (the “Amendment”).

 

WHEREAS the Letter appointed Pollack as Chief Financial Officer
(“CFO”) of the Company;

 

WHEREAS the Company has requested that Pollack provide services
beneficial to the Company that are beyond the scope of the Letter (the “Services”);

 

WHEREAS Pollack has not been receiving any cash compensation
to date and has received an amount of options deemed by the Company to be inadequate to retain Pollack as CFO;

 

WHEREAS the Company seeks to retain Pollack as CFO; and

 

WHEREAS the Company seeks to provide Pollack with additional
incentive to remain CFO and perform the Services;

 

NOW THEREFORE, in consideration of the mutual covenants herein
contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties
hereby mutually agree to amend the Letter as follows:

 

		1)	Pollack shall provide the Services until one (1) year from the date hereof.

 

		2)	Any compensation granted herein shall be in addition to any other option compensation previously granted by the Company to
Pollack and in addition to any accrued cash compensation owed by the Company to Pollack.

 

		3)	Effective January 1, 2013, Pollack shall receive annual cash pay of US$250,000.00 unless otherwise agreed in writing by the
Parties. Such pay shall be paid to Pollack in US$62,500.00 quarterly cash installments on the first day of each calendar quarter
of service: January 1, April 1, July 1, and October 1 of each year. Notwithstanding the foregoing, such annual cash pay shall be
deferred until the earlier of the date on which the Company is acquired or the date on which the Company is sufficiently funded
or partially funded, as determined by a majority of the Board of Directors of the Company, at which point all (or a portion of,
if partially funded) unpaid installments to such date on which the Company shall be funded shall be paid to Pollack within a reasonable
amount of time and shall not be unreasonably withheld. Once the Company is appropriately funded, as determined by a majority of
the Board of Directors of the Company, the Company shall pay Pollack competitive and reasonable cash compensation on a quarterly
basis, the amount of which shall be determined in good faith by Pollack and the Company at the time that such funding is received
by the Company.

 

    	 

    	 

    

 

		4)	Pollack shall accrue paid time off (“PTO”) at the rate of 25 days for each calendar year, prorated as applicable
for any particular calendar year and subject to the terms of the Company’s vacation policy. PTO is meant to include all vacation,
personal, and sick days. Pollack shall be compensated at the usual rate of cash compensation for any PTO. Pollack shall also be
entitled to paid Company Holidays as generally given by the Company, which are currently defined to include New Year’s Day,
Memorial Day, Independence Day, Labor Day, the day before Thanksgiving Day, Thanksgiving Day, and Christmas Day.

 

		5)	Pollack shall be eligible to participate in the benefit plans established for Company senior management and officers, including
group life, health, and dental coverage; in each case to the same extent and in the same manner as other similarly situated executives.
Nothing herein shall be constructed to limit, condition or otherwise encumber the Company’s right to amend, discontinue,
substitute or maintain any employee benefits plan, program or perquisite.

 

		6)	Pollack shall be granted the following options, all of which shall vest on the date hereof: (a) stock options for two million
five hundred thousand (2,500,000) shares of stock of the Company, exercisable at US$0.12 with the life of such option being ten
(10) years; and (b) stock options for six million five hundred thousand (6,500,000) shares of stock of the Company, exercisable
at US$0.15 with the life of such options being five (5) years (collectively, the “Options”). Such Options shall be
exercisable in the form of Notice of Stock Option Grant attached as Exhibit A hereto, which Options may be exercised, where applicable,
pursuant to the form of Notice of Exercise of Stock Option (the “Exercise Notice”) attached as Exhibit B hereto. Notwithstanding
any provisions of the Options to the contrary, if the fair market value of one share of Common Stock (as defined in the Stock Option
Plan of the Company effective December 15, 2010 (the “Stock Option Plan”)) is greater than the relevant exercise price
(“Exercise Price”) (at the date of calculation as set forth below), in lieu of exercising the Options for cash, the
Holder (as defined in the Stock Option Plan) may elect to receive shares equal to the value (as determined below) of the Options
(or the portion thereof being exercised) by surrender of the Options at the principal office of the Company together with the properly
signed Exercise Notice in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the
following formula:

 

    	 

    	 

    

 

	X=	Y(A-B)
	 	     A
	 	 
	Where X =	the number of shares of Common Stock to be issued to the Holder
	 	 
	Y =	the number of shares of Common Stock purchasable under the Options or, if only a portion of the Options are being exercised, the portion of the Options being exercised (at the date of such calculation)
	 	 
	A =	the fair market value of one share of the Company’s Common Stock (at the date of such calculation)
	 	 
	B =	the Exercise Price per share (as adjusted to the date of such calculation)

 

Notwithstanding the foregoing, such Options referenced
in (b) above may only be exercised between the following dates: (i) the earliest date on which the price per share of the Company’s
Common Stock has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and
(ii) their expiration date. Proportionate adjustments shall automatically be made to both the Exercise Prices and number of all
such Options referenced herein, and the price per share restriction set forth in this paragraph, if applicable, in the event of
a stock split, stock dividend, reclassification, recapitalization, or any other increase or decrease in the number of issued shares
of Company’s Common Stock effected without receipt of consideration by the Company, or upon any other event reasonably determined
by a majority of the Board of Directors of the Company to justify such adjustments.

 

Within one (1) month following the date hereof, the
Company shall deliver to Pollack all Options granted herein. All such Options delivered to Pollack as per this Amendment may be
delivered to Pollack electronically with a scanned signature, in which case they shall have the same effect and force as if they
had been delivered in original signed form. For all Options granted to Pollack electronic delivery of a signed Exercise Notice
along with electronic delivery of such Options shall have the same exercise effect as surrendering such Options at the principal
office of the Company together with the properly signed Exercise Notice.

 

All shares of the Company’s Common Stock underlying
the Options set forth above shall be delivered in registered and freely transferrable form. Within one (1) year from the date hereof,
the Company shall register all such stock under the Securities Act of 1933, as amended, to ensure that registered and freely transferrable
Common Stock shall be delivered to Pollack upon the exercise of the Options. Within one (1) year from the date hereof the Company
shall adopt a stock incentive plan that is tax-efficient for Pollack.

 

    	 

    	 

    

 

		7)	Pollack shall be granted warrants for five million five hundred thousand (5,500,000) shares of stock of the Company, exercisable
at US$0.15 with the life of such warrants being five (5) years from the date hereof (the “Warrants”). Such Warrants
shall be exercisable in the form of Notice of Warrant Grant attached as Exhibit C hereto, which Warrants may be exercised, where
applicable, pursuant to the form of Notice of Exercise of Warrant (the “ Warrant Exercise Notice”) attached as Exhibit
D hereto. The Warrants shall be exercisable in whole or in part, are only exercisable for cash, and are freely transferable to
other parties except as prohibited by applicable laws and regulations. Subject to the restrictions and requirements of applicable
law, the Warrants are exchangeable at any time for an equal aggregate number of warrants of different denominations, as reasonably
requested by the holder of the Warrants surrendering the same, or in such denominations as may be requested by the holder of the
Warrants (but not exceeding the number of Warrants granted).

 

Notwithstanding the foregoing, such Warrants may only
be exercised between the following dates: (i) the earliest date on which the price per share of the Company’s Common Stock
has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) their
expiration date. Proportionate adjustments shall automatically be made to both the Exercise Price and number of such Warrants,
and the price per share restriction set forth in this paragraph, in the event of a stock split, stock dividend, reclassification,
recapitalization, or any other increase or decrease in the number of issued shares of the Company’s Common Stock effected
without receipt of consideration by the Company, or upon any other event reasonably determined by a majority of the Board of Directors
of the Company to justify such adjustments.

 

Within one (1) month following the date hereof, the
Company shall deliver to Pollack such Warrants in original signed form. For all Warrants granted to Pollack electronic delivery
of a signed Warrant Exercise Notice along with electronic delivery of such Warrants shall have the same exercise effect as surrendering
such Warrants at the principal office of the Company together with the properly signed Warrant Exercise Notice.

 

All shares of the Company’s Common Stock underlying
the Warrants set forth above shall be delivered in registered and freely transferrable form. Within one (1) year from the date
hereof, the Company shall register all such stock under the Securities Act of 1933, as amended, to ensure that registered and freely
transferrable Common Stock shall be delivered to Pollack upon the exercise of the Warrants.

 

    	 

    	 

    

 

		8)	In the event of termination pursuant to Section 6 of the Letter, the Company shall not be obligated to provide any further
compensation to Pollack except such options that have vested, such warrants that have been granted, and any other cash or non-cash
compensation, including deferred cash compensation, to which Pollack is entitled through the date of such termination. Upon any
termination of Pollack by the Company that is not for a reason set forth in Section 6 of the Letter, upon the death of Pollack,
or upon a Constructive Termination, the Company shall pay Pollack the higher of his then current annual cash pay or the annual
cash pay set forth herein, in quarterly cash installments for four quarters from such date of termination, Constructive Termination,
or death. Constructive Termination means: (i) a reduction in annual cash pay or a material adverse change to the incentive plan
that affects Pollack differentially and adversely from other employees, management, and/or officers with comparable levels of responsibility;
(ii) upon the Company’s or its successor’s reasonable request, Pollack refuses to relocate to a facility or location
more than ten (10) miles from Pollack’s then current location; (iii) if Pollack is subjected to discrimination, harassment
or abuse as a result of his race, color, religion, creed, sex, age, national origin, sexual orientation, or disability; (iv) a
failure of a successor of the Company to assume the obligations of this Amendment; or (v) a material breach by the Company of this
Amendment.

 

		9)	This Amendment shall be governed by and construed in accordance with the laws of the United States, and specifically the laws
of the state of Nevada. Should a dispute arise, both parties shall subject themselves to exclusive jurisdiction of the courts of
the state of Nevada.

 

		10)	This Amendment and the Letter constitute the entire understanding between the Parties relating to its subject matter, superseding
all negotiations, prior discussions, preliminary agreements and agreements relating to the subject matter hereof made prior to
the date hereof. No waiver by a Party of any breach by another Party of any term, provision or condition of this Amendment, to
be performed by such other Party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same time or
at any prior or subsequent time. This Amendment may not be modified or amended except in writing signed by the Parties. Each of
the Parties hereto agrees that this Amendment has been jointly prepared, and that no claim may be asserted by any Party that any
ambiguity in this Amendment may be construed against any one Party. Except as expressly herein amended, all of the terms and conditions
of the Letter shall continue in full force and effect, and the same are hereby ratified and confirmed. In the event of an inconsistency
or conflict between any terms or conditions in the Letter and in this Amendment, the terms in this Amendment shall govern.

 

    	 

    	 

    

 

		11)	This Amendment may be executed in counterparts, each of which shall constitute an original but together shall constitute one
and the same Amendment. The Parties further agree that such counterparts may be provided via scan, email, and/or facsimile to one
another, each of which shall be binding upon the signatory who sends the scan, email and/or facsimile that was signed by such sending
signatory. The Parties further agree to exchange the original signature pages hereof as soon as practicable after sending such
scan, email and/or facsimile, but in any dispute or controversy, the Parties hereto agree that it shall not be necessary for any
such Party to provide the original signature pages of the other as a condition of enforcing this Amendment, it being understood
that such scan, email and/or facsimile signature pages shall be sufficient to establish the consent of the Party who sent the scan,
email and/or facsimile that was signed by such sending signatory to be bound by the terms of this Amendment.

 

IN WITNESS WHEREOF the parties have executed
this Amendment this 31st day of December 2012.

 

LIGHTLAKE THERAPEUTICS INC.

 

	By:	/s/ Roger Crystal	 
	Name:	Roger Crystal	 
	Title:	CEO	 
	 	 	 
	By:	/s/ Kevin Pollack	 
	Name:	Kevin Pollack	 
	Title:	Chief Financial Officer	 

 

EXHIBIT A

 

FORM OF NOTICE OF STOCK OPTION GRANT

 

Dear Mr. ________________ (“Optionee”),

 

Reference is hereby made to (i) the Stock Option Plan of Lightlake
Therapeutics Inc. (the “Company”) effective December 15, 2010 (the “Stock Option Plan”),
and (ii) the Executive Letter of Appointment dated November 26, 2012, between the Company and Kevin Pollack, Esq and the Amendment
to the Executive Letter of Appointment dated _______________ __, ____, between the Company and Kevin Pollack, Esq. (as amended,
restated, or otherwise modified from time to time, the “Letter”). Capitalized terms utilized herein shall have
the meanings ascribed to them in the Stock Option Plan unless otherwise defined herein.

 

    	 

    	 

    

 

You have been granted
options to purchase Common Stock of the Company (with each share of Common Stock of the Company, a “Share”)
as follows:

 

	Board Approval Date:	 
	 	 
	Date of Grant:	 
	 	 
	Exercise Price per Share:	[US$0.12 or US$0.15, as appropriate]
	 	 
	Total Number of Shares Granted:	 
	 	 
	Total Exercise Price:	Cashless exercise as per the Letter
	 	 
	Type of Options:	Non-Qualified Stock Options
	 	 
	Expiration Date:	[The date that is ten (10) years or five (5) years from the Date of Grant, as appropriate]
	 	 
	Termination Period:	These Options may be exercised for a period of ten (10) years or five (5) years from the Date of Grant, as appropriate.  Optionee is responsible for keeping track of these exercise periods following termination for any reason of his service relationship with the Company, it being understood that Optionee is entitled to all rights, including compensation and vesting rights, with respect to these Options, as set forth in the Letter.  The Company will not provide further notice of such periods.
	 	 
	Transferability:	These Options may not be transferred, except as permitted by applicable laws and regulations.
	 	 
	Restrictions on Exercise:	[With respect to the Options with the US$0.15 Exercise Price and five (5) year life: These Options may only be exercised between the following dates: (i) the earliest date on which the price per Share has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) the Expiration Date.]  Notwithstanding anything to the contrary contained in any agreement with the Company, it is an absolute condition of the Optionee’s right to exercise any Option that the Optionee be in full compliance with any other agreements between the Optionee and the Company, including without limitation any confidentiality agreements.

 

    	 

    	 

    

 

	Vesting:	100% on [the date of the initial Amendment to the Executive Letter of Appointment referenced herein]

 

Following receipt by
the Company of evidence and/or an indemnity from the Optionee to the Company in a form reasonably satisfactory to the Company of
the loss, theft, destruction or mutilation of these Options or any certificates for representing the Shares underlying these Options
and, in the event of mutilation, following the surrender and cancellation of such Options or stock certificate, the Company will
make and deliver replacement Options or stock certificate of like tenor and dated as of such cancellation, in lieu of these Options
or stock certificates, without any charge therefor, it being understood that the making and/or delivery of such replacement Options
or stock certificates by the Company will not be unreasonably withheld.  Any such replacement Options or stock certificates
shall be subject to the same terms, conditions, and restrictions as these Options and any Shares underlying these Options. Subject
to the restrictions and requirements of applicable law, these Options are exchangeable at any time for an equal aggregate number
of options of different denominations, as reasonably requested by the Optionee surrendering the same, or in such denominations
as may be requested by the Optionee (but not exceeding the number of Shares underlying the Options in these Options in the aggregate). 
No service charge will be made for such registration or transfer, exchange or reissuance. Proportionate adjustments shall automatically
be made to both the Exercise Price and number of these Options, and the Restrictions on Exercise [if applicable], in the event
of a stock split, stock dividend, reclassification, recapitalization, or any other increase or decrease in the number of issued
Shares of the Company effected without receipt of consideration by the Company, or upon any other event reasonably determined by
a majority of the Board of Directors of the Company to justify such adjustments.

 

Shares issued to you
upon exercise of these Options shall be registered under the Securities Act of 1933, as amended, and shall be freely transferrable.
To the extent that the terms of the Stock Option Plan differ from the terms of this Notice of Stock Option Grant (the “Notice”),
the terms of this Notice supersede the terms of the Stock Option Plan.

 

By your signature and
the signature of the Company’s representative below, you and the Company agree to the terms of these Options.

 

	 	 	LIGHTLAKE THERAPEUTICS INC.
	 	 	 
	 	 	 
	Optionee	 	Roger Crystal, Chief Executive Officer

 

    	 

    	 

    

 

EXHIBIT B

 

Form of Notice of Exercise of Stock
Option

 

Ladies and Gentlemen:

 

This letter constitutes an unconditional
and irrevocable notice that I hereby exercise the stock option(s) granted to me by Lightlake Therapeutics Inc., a Nevada corporation
(the “Company”) on _______________ at a fair market value of US$ ______ per share. Pursuant to the terms of
such option(s), I wish to purchase _______________ shares of the common stock covered by such option(s) at the exercise price(s)
of US$ ______ per share via cashless exercise. These shares should be registered under the Securities Act of 1933, as amended,
and delivered as follows:

 

	Name:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number:	 	 

 

I represent that I will not dispose of such
shares in any manner that would involve a violation of applicable securities laws.

 

	Dated:	 	 	By:	 	 
	 	 	 	 	 	 
	 	 	 	Name:	 	 

 

    	 

    	 

    

 

EXHIBIT C

 

FORM OF NOTICE OF WARRANT GRANT

 

Dear Mr. ________________ (“Warrant Holder”),

 

As per the Amendment
to the Executive Letter of Appointment dated _______________ __, ____, between Lightlake Therapeutics Inc. (the “Company”)
and Kevin Pollack, Esq., the Warrant Holder has been granted warrants (“Warrants”) to purchase Common Stock of the
Company (with each share of Common Stock of the Company, a “Share”) as follows:

 

	Board Approval Date:	 
	 	 
	Date of Grant:	 
	 	 
	Exercise Price per Share:	US$0.15
	 	 
	Total Number of Warrants Granted:	 
	 	 
	Total Exercise Price:	US$0.15 per Warrant
	 	 
	Expiration Date:	[The date that is five (5) years from the Date of Grant]
	 	 
	Termination Period:	These Warrants may be exercised for a period of five (5) years from the Date of Grant.
	 	 
	Transferability:	These Warrants may be transferred, except as prohibited by applicable laws and regulations.
	 	 
	Vesting:	100% on [the date of the initial Amendment to the Executive Letter of Appointment referenced herein.]
	 	 
	Restriction on Exercise:	These Warrants may only be exercised between the following dates: (i) the earliest date on which the price per Share has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) the Expiration Date.

 

    	 

    	 

    

 

Following receipt by
the Company of evidence and/or an indemnity from the Warrant Holder to the Company in a form reasonably satisfactory to the Company
of the loss, theft, destruction or mutilation of these Warrants or any certificates for representing the Shares underlying these
Warrants and, in the event of mutilation, following the surrender and cancellation of such Warrants or stock certificate, the Company
will make and deliver replacement Warrants or stock certificate of like tenor and dated as of such cancellation, in lieu of these
Warrants or stock certificates, without any charge therefor, it being understood that the making and/or delivery of such replacement
Warrants or stock certificates by the Company will not be unreasonably withheld.  Any such replacement Warrants or stock certificates
shall be subject to the same terms, conditions, and restrictions as these Warrants and any Shares underlying these Warrants. Subject
to the restrictions and requirements of applicable law, these Warrants are exchangeable at any time for an equal aggregate number
of warrants of different denominations, as reasonably requested by the Warrant Holder surrendering the same, or in such denominations
as may be requested by the Warrant Holder (but not exceeding the number of Shares underlying the Warrants in these Warrants in
the aggregate).  No service charge will be made for such registration or transfer, exchange or reissuance. Proportionate adjustments
shall automatically be made to both the Exercise Price and number of these Warrants, and the Restriction on Exercise, in the event
of a stock split, stock dividend, reclassification, recapitalization, or any other increase or decrease in the number of issued
Shares of the Company effected without receipt of consideration by the Company, or upon any other event reasonably determined by
a majority of the Board of Directors of the Company to justify such adjustments.

 

Shares issued to the
Warrant Holder upon exercise of these Warrants shall be registered under the Securities Act of 1933, as amended, and shall be freely
transferrable.

 

By signature of the Warrant
Holder and the signature of the Company’s representative below, the Warrant Holder and the Company agree to the terms of
these Warrants.

 

	 	 	LIGHTLAKE THERAPEUTICS INC.
	 	 	 
	 	 	 
	Warrant Holder	 	Roger Crystal, Chief Executive Officer

 

EXHIBIT D

 

Form of Notice of Exercise of Warrant

 

Ladies and Gentlemen:

 

This letter constitutes an unconditional
and irrevocable notice that I hereby exercise the warrant(s) granted to me by Lightlake Therapeutics Inc., a Nevada corporation
(the “Company”) on _______________ at a fair market value of US$ ______ per share. Pursuant to the terms of
such warrant(s), I wish to purchase _______________ shares of the common stock covered by such warrant(s) at the exercise price(s)
of US$ ______ per share via cash exercise, for a total aggregate purchase price of US$_______________, which I agree to promptly
provide to the Company.

 

    	 

    	 

    

 

Electronic delivery of this signed notice along with electronic
delivery of such warrant(s) shall have the same exercise effect as surrendering such warrant(s) at the principal office of the
Company together with the properly signed Notice of Exercise of Warrant.

 

These shares should be registered under the Securities Act of
1933, as amended, and delivered as follows:

 

	Name:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number:	 	 

 

I represent that I will not dispose of such
shares in any manner that would involve a violation of applicable securities laws.

 

	Dated:	 	 	By:	 	 
	 	 	 	 	 	 
	 	 	 	Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]